Healthy-Looking Prostate Cells Mask Cancer-Causing Mutations
By LabMedica International staff writers Posted on 18 Mar 2015 |
Image: The MiSeq desktop sequencer (Photo courtesy of Konrad Förstner).
Genome-wide DNA sequencing has been used to decrypt the phylogeny of multiple samples from distinct areas of cancer and morphologically normal tissue taken from the prostates of individuals.
Prostate cancer is often made up of many small tumors with different genetic fingerprints, and it is still unclear what causes these different tumors to develop in the prostate at the same time, but new studies provides a piece of the puzzle that could help solve the mystery.
A large team of scientists led by the Institute of Cancer Research (London, UK) collected samples for analysis from prostatectomy patients. Prostates were sliced and processed and a single 5-mm slice of the prostate was selected for analysis purposes, and 4-mm or 6-mm cores were taken from the slice and frozen. Frozen cores were mounted vertically and sectioned transversely to create one 5-μm frozen section for staining and six 50-μm sections for DNA preparation.
The V-Ets Avian Erythroblastosis Virus E26 Oncogene Homolog (ERG) fluorescence in situ hybridization (FISH) break-apart assay for assessing ERG gene rearrangement was performed. DNA was extracted from 18 samples from three subjects: 12 prostate cancer samples; three adjacent, morphologically normal prostate samples; and three matched bloods. Paired-end genome-wide sequencing (GWS) of the samples was also performed. Targeted polymerase chain reaction (PCR) and sequencing of selected mutations and structural variants were analyzed for each sample using a MiSeq sequencer (Illumina, Inc.; San Diego, CA, USA).
The results suggest that large numbers of normal-looking prostate cells have a variety of genetic faults and cancer could develop from any of them. This could explain why prostate cancer is often made up from multiple genetically different tumors and suggests that prostate cancer development begins earlier than scientists thought. The findings may lead to a rethink of prostate cancer treatment, in which these precancerous cells are destroyed at the same time as the tumor cells.
Rosalind Eeles, FMedSci, MA, FCRP, FRCR, PhD, a professor of Oncogenetics and senior author of the study said, “When we examine the cells that lie close to prostate cancer under the microscope, we look at their shape, size and relationship to surrounding cells. If everything appears normal then we may assume that we're looking at healthy tissue. But thanks to genetic sequencing we've shown that some of these normal-looking cells are already carrying genetic mistakes that are linked to the cancer nearby. This study helps us understand more about the beginnings of prostate cancer, so we can tackle the disease at its roots.” The study was published on March 2, 2015, in the journal Nature Genetics.
Related Links:
The Institute of Cancer Research
Illumina, Inc.
Prostate cancer is often made up of many small tumors with different genetic fingerprints, and it is still unclear what causes these different tumors to develop in the prostate at the same time, but new studies provides a piece of the puzzle that could help solve the mystery.
A large team of scientists led by the Institute of Cancer Research (London, UK) collected samples for analysis from prostatectomy patients. Prostates were sliced and processed and a single 5-mm slice of the prostate was selected for analysis purposes, and 4-mm or 6-mm cores were taken from the slice and frozen. Frozen cores were mounted vertically and sectioned transversely to create one 5-μm frozen section for staining and six 50-μm sections for DNA preparation.
The V-Ets Avian Erythroblastosis Virus E26 Oncogene Homolog (ERG) fluorescence in situ hybridization (FISH) break-apart assay for assessing ERG gene rearrangement was performed. DNA was extracted from 18 samples from three subjects: 12 prostate cancer samples; three adjacent, morphologically normal prostate samples; and three matched bloods. Paired-end genome-wide sequencing (GWS) of the samples was also performed. Targeted polymerase chain reaction (PCR) and sequencing of selected mutations and structural variants were analyzed for each sample using a MiSeq sequencer (Illumina, Inc.; San Diego, CA, USA).
The results suggest that large numbers of normal-looking prostate cells have a variety of genetic faults and cancer could develop from any of them. This could explain why prostate cancer is often made up from multiple genetically different tumors and suggests that prostate cancer development begins earlier than scientists thought. The findings may lead to a rethink of prostate cancer treatment, in which these precancerous cells are destroyed at the same time as the tumor cells.
Rosalind Eeles, FMedSci, MA, FCRP, FRCR, PhD, a professor of Oncogenetics and senior author of the study said, “When we examine the cells that lie close to prostate cancer under the microscope, we look at their shape, size and relationship to surrounding cells. If everything appears normal then we may assume that we're looking at healthy tissue. But thanks to genetic sequencing we've shown that some of these normal-looking cells are already carrying genetic mistakes that are linked to the cancer nearby. This study helps us understand more about the beginnings of prostate cancer, so we can tackle the disease at its roots.” The study was published on March 2, 2015, in the journal Nature Genetics.
Related Links:
The Institute of Cancer Research
Illumina, Inc.
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans